Probiodrug is a biopharmaceutical company focused on the development of innovative small-molecule drugs targeting key enzymes for the treatment of neuronal, inflammatory and autoimmune diseases. The company was founded in 1997 and has raised a total of €57 million for its present programmes. The company is located in Halle, Germany, and has a subsidiary in Martinsried/Munich, Germany. Probiodrug has an outstanding track record in elucidating the structure and function of enzymes involved in the maturation and modification of peptides (hormones, others) and the development of enzyme inhibitors as novel drug candidates. It has pioneered the field of dipeptidyl peptidase-4 (DPP-4) inhibition for the treatment of Type II diabetes. Currently, small molecule inhibitors of glutaminyl cyclase (QC) are developed as novel treatments for Alzheimer's (AD) and certain inflammatory diseases.